When one depends on the other: Reporting of interaction in case-control and cohort studies

Epidemiology

Volumn 20, Issue 2, 2009, Pages 161-166

  Knol, Mirjam J ^a,b,c   Egger, Matthias ^c,d   Scott, Pippa ^c   Geerlings, Mirjam I ^a   Vandenbroucke, Jan P ^e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE CONTROL STUDY; CLINICAL RESEARCH; COHORT ANALYSIS; DATA ANALYSIS; EXPOSURE; PRIORITY JOURNAL; QUALITY CONTROL; STATISTICAL ANALYSIS; BIBLIOMETRICS; EPIDEMIOLOGY;

BIBLIOMETRICS; CASE-CONTROL STUDIES; CAUSALITY; COHORT STUDIES; EPIDEMIOLOGIC STUDIES;

EID: 66149106310     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e31818f6651     Document Type: Article

References (32)

1. Ahlbom A, Alfredsson L. Interaction: a word with two meanings creates confusion. Eur J Epidemiol. 2005;20:563-564.
2. Botto LD, Khoury MJ. Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol. 2001;153:1016-1020.
3. Greenland S, Poole C. Invariants and noninvariants in the concept of interdependent effects. Scand J Work Environ Health. 1988;14:125-129.
4. Rothman KJ. Synergy and antagonism in cause-effect relationships. Am J Epidemiol. 1974;99:385-388.
5. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol. 1980;112:467-470.
6. Rothman KJ. Interactions between causes. In: Modern Epidemiology. Boston, Toronto: Little Brown and Company; 1986:311:-326.
7. Greenland S, Rothman KJ. Concepts of interaction. In: Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998:329-342.
8. VanderWeele TJ, Robins JM. The identification of synergism in the sufficient-component-cause framework. Epidemiology. 2007;18:329-339.
9. Siemiatycki J, Thomas DC. Biological models and statistical interactions: an example from multistage carcinogenesis. Int J Epidemiol. 1981;10:383-387.
10. Thompson WD. Effect modification and the limits of biological inference from epidemiologic data. J Clin Epidemiol. 1991;44:221-232.
11. Vandenbroucke JP, von EE, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.
12. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology. 1992;3:452-456.
13. Knol MJ, van der Tweel I, Grobbee DE, et al. Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol. 2007;36:1111-1118.
14. Knol MJ, Vandenbroucke JP, Scott P, et al. What do case-control studies estimate? Survey of methods and assumptions in published case-control research. Am J Epidemiol.
15. September 2008. [Epub ahead of print].
16. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366: 649-659.
17. Folsom AR, Cushman M, Heckbert SR, et al. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol. 2003;56:598-603.
18. Tavani A, Bertuzzi M, Gallus S, et al. Diabetes mellitus as a contributor to the risk of acute myocardial infarction. J Clin Epidemiol. 2002;55: 1082-1087.
19. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.
20. Lazo-Langner A, Knoll GA, Wells PS, et al. The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene. Blood. 2006;108:4052-4058.
21. Schriger DL, Sinha R, Schroter S, et al. From submission to publication: a retrospective review of the tables and figures in a cohort of randomized controlled trials submitted to the British Medical Journal. Ann Emerg Med. 2006;48:750-756.
22. Pocock SJ, Collier TJ, Dandreo KJ, et al. Issues in the reporting of epidemiological studies: a survey of recent practice. BMJ. 2004;329:883.
23. Moreira EDJr, Stein Z, Susser E. Reporting on methods of subgroup analysis in clinical trials: a survey of four scientific journals. Braz J Med Biol Res. 2001;34:1441-1446.
24. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis) uses of baseline data in clinical trials. Lancet. 2000;355:1064-1069.
25. Rothwell PM. Treating individuals
26. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-186.
27. Goodman SN. Multiple comparisons, explained. Am J Epidemiol. 1998; 147:807-812.
28. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
29. Szklo M, Nieto FJ. Communicating Results of Epidemiologic Studies Epidemiology, Beyond the Basics. Sudbury, MA: Jones and Bartlett; 2000:chap 9.
30. Greenland S. Additive risk versus additive relative risk models. Epidemiology. 1993;4:32-36.
31. Skrondal A. Interaction as departure from additivity in case-control studies: a cautionary note. Am J Epidemiol. 2003;158:251-258.
32. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies [in Spanish]. Ann Intern Med. 2007;147:573-577.